Gynecologic Oncology | Specialty

Tislelizumab/Sitravatinib Shows Early Antitumor Activity, Safety in Platinum-Resistant Epithelial Ovarian Cancer

April 11th 2021

The combination of tislelizumab and sitravatinib demonstrated early antitumor activity and a manageable safety profile in patients with recurrent platinum-resistant epithelial ovarian cancer and were naïve to PD-1/PD-L1 inhibition.

TAS-117 Shows Limited Efficacy in Ovarian, Breast Tumors

April 11th 2021

Treatment with TAS-117, a highly potent and selective oral allosteric pan-v-akt murine thymoma viral oncogene homolog inhibitor, demonstrated some clinical efficacy in patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.

Dr. Marron on an Adjuvant Personalized Neoantigen Peptide Vaccine for Several Malignancies

April 10th 2021

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

FDA Grants Priority Review to Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

April 9th 2021

The FDA has granted a priority review to the biologics license application for tisotumab vedotin as a potential treatment for patients with recurrent or metastatic cervical cancer with progressive disease on, or following, chemotherapy.

Pursuing PARP Beyond HRD+ Ovarian Cancer

April 9th 2021

Hye Sook Chon, MD, teases out some of the differences between the data with PARP inhibitors in the frontline maintenance setting and shed light on ongoing research with combinations that could broaden their utility in patients with advanced ovarian cancer.

Utility of HRD Testing in Ovarian Cancer Expands, But Standardization Remains Elusive

April 6th 2021

Two tests for homologous recombination deficiency have been FDA approved for patients with ovarian cancer, including myChoice CDx and FoundationOne CDx, and they produce important information that can be used to guide treatment decisions.

Study Examines Cost-Sharing Trends in PARP Inhibitors for Ovarian Cancer

April 2nd 2021

Out-of-pocket costs for patients with ovarian cancer who have been treated with PARP inhibitors are generally low, according to recent study results from a single institution.

Dr. Wenham on Future Directions with Antibody-Drug Conjugates in Ovarian Cancer

March 30th 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.

Mirvetuximab Soravtansine/Rucaparib Shows Early Tolerability, Activity in Ovarian and Endometrial Cancers

March 29th 2021

The combination of mirvetuximab soravtansine and rucaparib was found to be well tolerated, with encouraging activity reported in heavily pretreated patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer.

Coleman and Brown Review Advancing Applications for PARP Inhibition in Ovarian Cancer

March 25th 2021

Dr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.